- Previous Close
0.4878 - Open
0.4200 - Bid --
- Ask 0.4500 x 100
- Day's Range
0.4190 - 0.4627 - 52 Week Range
0.3900 - 117.7000 - Volume
2,167,570 - Avg. Volume
3,640,529 - Market Cap (intraday)
477,036 - Beta (5Y Monthly) 1.80
- PE Ratio (TTM)
-- - EPS (TTM)
-220.0000 - Earnings Date May 19, 2025 - May 23, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
hepionpharma.comRecent News: HEPA
View More
Performance Overview: HEPA
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HEPA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HEPA
View MoreValuation Measures
Market Cap
507.60k
Enterprise Value
2.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.11
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-110.40%
Return on Equity (ttm)
-288.27%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-22.7M
Diluted EPS (ttm)
-220.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.5M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-20.54M
Research Analysis: HEPA
View MoreResearch Reports: HEPA
View MoreDaily – Vickers Top Insider Picks for 03/01/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/26/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/25/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/24/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.